Provided by Tiger Trade Technology Pte. Ltd.

Capricor Therapeutics

9.06
-0.3600-3.82%
Post-market: 9.05-0.0100-0.11%19:59 EDT
Volume:3.26M
Turnover:29.57M
Market Cap:526.74M
PE:-3.67
High:9.36
Open:9.30
Low:8.96
Close:9.42
52wk High:40.37
52wk Low:2.96
Shares:58.14M
Float Shares:45.54M
Volume Ratio:1.21
T/O Rate:7.15%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.4659
EPS(LYR):-2.2601
ROE:-73.70%
ROA:-33.63%
PB:2.14
PE(LYR):-4.01

Loading ...

Capricor to Present 24-Month HOPE-3 Data on Deramiocel in Duchenne Muscular Dystrophy at World Muscle Society Congress

Reuters
·
Sep 17

Capricor Therapeutics to Present HOPE-3 and HOPE-3 Open-Label Extension Data at 2026 World Muscle Society Congress

GlobeNewswire
·
Sep 17

Capricor Therapeutics Shares Rise After Upgrade From B. Riley

MT Newswires Live
·
Sep 15

B. Riley Upgrades Capricor Therapeutics to Buy From Neutral, Raises Price Target to $21 From $5

MT Newswires Live
·
Sep 14

Capricor Therapeutics upgraded to Buy from Neutral at B. Riley

TIPRANKS
·
Sep 14

U.S. Research Roundup-ACV Auctions, Crown Castle, Lennox International

Reuters
·
Sep 14

Capricor Therapeutics Shares Rise After Piper Sandler Upgrade

MT Newswires Live
·
Sep 02

Capricor Therapeutics Price Target Raised to $25.00/Share from $2.00 by Piper Sandler

Dow Jones
·
Sep 02

U.S. Stocks on the MOVE-GoPro, TXNM Energy, Emergent BioSolutions

Reuters
·
Sep 01

U.S. Stocks on the MOVE-Robinhood Markets, Park Hotels & Resorts, Capricor Therapeutics

Reuters
·
Sep 01

Capricor Therapeutics upgraded to Overweight from Neutral at Piper Sandler

TIPRANKS
·
Sep 01

Analysts Offer Insights on Healthcare Companies: Capricor Therapeutics (CAPR) and Helus Pharma (HELP)

TIPRANKS
·
Sep 01

U.S. Research Roundup-Autodesk, Hubspot, Oracle

Reuters
·
Sep 01

Capricor Therapeutics call volume above normal and directionally bullish

TIPRANKS
·
Aug 26

U.S. Stocks on the MOVE-Azenta, Qiagen NV, Capricor Therapeutics

Reuters
·
Aug 24

Capricor Therapeutics Shares Rise as FDA Extends Deramiocel Review

Dow Jones
·
Aug 24

Wainwright says Capricor’s regulatory risk still high after FDA PDUFA extension

TIPRANKS
·
Aug 24

Capricor's Duchenne Drug Gets Three-Month FDA Extension After New Data Submission

Reuters
·
Aug 24

US FDA Extends Review of Capricor's Muscle Disorder Therapy by Three Months

Reuters
·
Aug 24

Capricor PDUFA Date for Deramiocel DMD Therapy Shifts to Nov. 22, 2026 After FDA Review Extension

Reuters
·
Aug 24